Trial Profile
A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK-3358699 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 13 Nov 2021 Following a temporary halt to investigate cardiac-related adverse events during cohort 4, the study design was amended for cohorts 5-7, as per results published in the British Journal of Clinical Pharmacology
- 13 Nov 2021 Results published in the British Journal of Clinical Pharmacology
- 11 Feb 2020 Status changed from suspended to discontinued.